TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30610027
Drug: Online, remotely
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online, remotely delivered, therapist-supported exposure response prevention behavioural therapy for tics
Study: 20437287
Drug: Education session
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education session on drug-to-drug interactions
Study: 15767219
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg/day with telithromycin 800 mg/day
Study: 15767219
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (single-dose) with telithromycin 800 mg/day
Study: 12504970
Drug: Active management
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active management with oral misoprostol (50 microg every 4 hours, max 5 doses)
Study: 12504970
Drug: Active management
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active management with oral misoprostol
Study: 12504970
Drug: Conservative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management (induction with PGE(2) gel or oxytocin after 24 hours)
Study: 9803051
Drug: Ayurvedic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic formulation (Misrakasneham)
Study: 9803051
Drug: Conventional laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional laxative tablet (Sofsena)
Study: 8613310
Drug: Furazolidone treatment
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furazolidone treatment
Study: 25003812
Drug: Intramuscular clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular clodronate 100mg/week (CLO) (N=36)
Study: 25003812
Drug: Yearly intravenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yearly intravenous therapy with 5mg zoledronate (ZOL) (N=18)
Study: 15203809
Drug: Bupropion treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion treatment
Study: 17895350
Drug: Extension-oriented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extension-oriented treatment approach (EOTA)
Study: 15354104
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between aspirin and clopidogrel
Study: 12495795
Drug: Novel cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel cognitive-behavioral treatment (CBT)
Study: 2260146
Drug: High-risk approach
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk approach with drugs to reduce risk factors in individuals with high levels
Study: 6779673
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion of 7.8 microgram . kg‐1 . mn‐1 (Group I)
Study: 6779673
Drug: No vasodilator
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vasodilator drug (Group II)
Study: 31813763
Drug: Pharmacist-led medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacist-led medicines review intervention (medicines education session, medicines optimisation session)
Study: 31813763
Drug: Pharmacist-led medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacist-led medicines review intervention
Study: 11837466
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (2 grams elemental calcium daily from 20 weeks of gestation to delivery)
Study: 9497178
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g psyllium seed husk (control)
Study: 2529108
Drug: GR 38032F
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR 38032F (0.15 mg/kg)
Study: 1068646
Drug: Antimicrobial prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial prophylaxis with oral nonabsorbed antibiotics and a nasal antibiotic ointment
Study: 30528592
Drug: Ebola vaccine
Normalized name: ebola vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebola vaccine trial participants
Study: 30528592
Drug: Adjuvanted seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted seasonal influenza vaccine trial participants
Study: 23799922
Drug: LAN 90
Normalized name: melphalan 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAN 90 mg
Study: 23799922
Drug: LAN 120
Normalized name: Calan 120mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAN 120 mg
Study: 21406998
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) 60-100 mg
Study: 14734517
Drug: Selective adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective adenosine A2A receptor agonist binodenoson (various doses)
Study: 25336668
Drug: CPVI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPVI + SVC-L
Study: 16841676
Drug: Shenmai Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai Injection (SI) with chemotherapy
Study: 8858271
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg N-acetylcysteine (NAC) for 4 months
Study: 1620143
Drug: L-DOPA methyl
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPA methyl ester
Study: 29354929
Drug: Five needles
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five needles therapy
Study: 22229478
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg p.o.
Study: 20535920
Drug: Salviae injection
Normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salviae injection and ligustrazine injection (S & L) in combination with conventional Western medical treatment
Study: 20535920
Drug: Salviae injection
Normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salviae injection and ligustrazine injection (S & L)
Study: 8630464
Drug: Fast antipyrine
Normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast antipyrine metabolism in lung cancer patients and their first degree relatives
Study: 8630464
Drug: Intermediate antipyrine
Normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate antipyrine metabolism
Study: 8630464
Drug: Slow antipyrine
Normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow antipyrine metabolism
Study: 1353720
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion (250 micrograms/h for 96 h)
Study: 1353720
Drug: Intramuscular Gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Gold salts
Study: 1353720
Drug: Gold salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold salts for 8 months with Somatostatin infusion at the fourth month
Study: 30627845
Drug: 9 serial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 serial mud baths within 21 days in addition to a multimodal physical rehabilitative complex treatment
Study: 30627845
Drug: Only physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only physical rehabilitative treatment without mud baths
Study: 17356110
Drug: Sildenafil therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil therapy for 3 months
Study: 2892458
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg a day
Study: 2892458
Drug: Betaxolol 20
Normalized name: betaxolol 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 20 mg a day
Study: 29560570
Drug: Monthly vaginal
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly vaginal ring
Study: 29600595
Drug: Monthly intramuscular
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly intramuscular injections
Study: 29600595
Drug: Injections
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections
Study: 29600595
Drug: Tablets and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets and rings
Study: 27294814
Drug: Mozart music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mozart music (Symphony No. 40 in g minor, KV 550)
Study: 24552320
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg) plus chemotherapy (cisplatin-paclitaxel or topotecan-paclitaxel)
Study: 24552320
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (cisplatin-paclitaxel or topotecan-paclitaxel)
Study: 1621496
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine sulphate
Study: 1621496
Drug: 0.02 mg
Normalized name: escin 0.02 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg fentanyl citrate
Study: 1621496
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg meperidine hydrochloride
Study: 1621496
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml saline
Study: 2418306
Drug: Oral nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nicardipine
Study: 28544215
Drug: Smooth neck
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smooth neck implant (1.5 mm)
Study: 21815991
Drug: Rough neck
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rough neck implant with grooves
Study: 28544215
Drug: Scalloped rough
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalloped rough neck implant with grooves
Study: 26629926
Drug: Lactulose mannitol
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose mannitol solution
Study: 26629926
Drug: Aspirin solution
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin solution (600 mg)
Study: 26629926
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid solution (500 mg)
Study: 26629926
Drug: Various solutions
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various solutions (lactulose mannitol, aspirin, ascorbic acid, blackcurrant)
Study: 18855810
Drug: Topiramate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (300 mg/day)
Study: 16790039
Drug: Minimal psychological
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal psychological intervention (MPI) administered by trained nurses
Study: 12681876
Drug: Gemeprost (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemeprost (1 mg)
Study: 8888329
Drug: 11 mg/day
Normalized name: ProStep 11 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 mg/day transdermal nicotine
Study: 8888329
Drug: 22 mg/day
Normalized name: ProStep 22 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 mg/day transdermal nicotine
Study: 8888329
Drug: 44 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 mg/day transdermal nicotine
Study: 1511080
Drug: Clomipramine (CMI)
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine (CMI) 175-250 mg/day
Study: 6628802
Drug: Khellin treatment
Normalized name: khellin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Khellin treatment
Study: 29360560
Drug: Lidocaine dual-responsive
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine dual-responsive in situ gel (2% lidocaine)
Study: 27160246
Drug: icosabutate 600
Normalized name: Ethyl icosapentate
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: icosabutate 600 mg once daily
Study: 24996489
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of controlled-release simvastatin 20 mg
Study: 24996489
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration of immediate-release simvastatin 20 mg
Study: 22913681
Drug: Eltrombopag (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (75 mg daily for 14 days)
Study: 16316352
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid (AA) infusion
Study: 9202909
Drug: Nasal midazolam
Normalized name: midazolam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal midazolam (0.2 mg kg‐1, 5 mg ml‐1)
Study: 9202909
Drug: Rectal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal midazolam (0.3 mg kg‐1 in 5 mL saline)
Study: 7962441
Drug: Progesterone (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (1.0 micrograms/ml)
Study: 24786217
Drug: Internal cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal cardioverter defibrillator-only therapy
Study: 23715050
Drug: LCP‐Tacro once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCP‐Tacro once-daily
Study: 24493215
Drug: Prograf twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prograf twice-daily
Study: 20443101
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alfa 2b (1.5 microg/kg/week) with ribavirin (12-15 mg/kg/day; group B)
Study: 18164145
Drug: Enhanced Services
Normalized name: SYRINGE SERVICES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Services (nurse-delivered manual-guided behavioral drug and HIV risk reduction counseling and abstinence-contingent take-home buprenorphine)
Study: 18164145
Drug: Standard Services
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Services (physician administered advice and support, and weekly, non-contingent medication pick-up)
Study: 16192247
Drug: Viral load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viral load > or =100,000 copies/mL
Study: 12645830
Drug: Salmeterol/fluticasone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone combination (SFC) 50/100 microg twice daily
Study: 12645830
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 microg twice daily plus oral montelukast (M) 10 mg once daily
Study: 12645830
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) plus oral montelukast (M)
Study: 10665126
Drug: Intravenous/oral trovafloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous/oral trovafloxacin (300 mg i.v. alatrofloxacin switching to 200 mg oral trovafloxacin)
Study: 10665126
Drug: Intravenous imipenem/cilastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid (1 g i.v. imipenem/cilastatin switching to 625 mg oral amoxycillin/clavulanic acid)
Study: 20340049
Drug: Short-stay intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-stay intensive care treatment (SSIC, 8 h of intensive care stay)
Study: 20340049
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (care as usual, overnight intensive care stay)
Study: 6344041
Drug: Diflunisal 1000
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflunisal 1000 mg
Study: 7665721
Drug: Lornoxicam 16
Normalized name: Lornoxicam 16 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 16 mg
Study: 10684124
Drug: Mixed tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed tea (3 g/day orally and 0.1% smeared on mucosa lesions three times a day for 3 months and 6 months)
Study: 10549685
Drug: Carbamazepine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (300 mg/day)
Study: 2617212
Drug: Erythromycin acistrate
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin acistrate 500 mg t.i.d. for 1 week
Study: 2617212
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate 500 mg t.i.d. for 1 week
Study: 31774037
Drug: Vorapaxar 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar 2.5 mg per day for 12 weeks
Study: 31273244
Drug: Intranasal AVP
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal AVP
Study: 25689743
Drug: High-fiber AXOS
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber AXOS (15 g)
Study: 25689743
Drug: High-fiber FLAX
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber FLAX (15 g)
Study: 25689743
Drug: Low-fiber (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fiber (4 g)
Study: 23751992
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L PEG plus ascorbic acid (PEG+Asc)
Study: 23751992
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L PEG plus simethicon (PEG+Sim)
Study: 22126115
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) program plus usual care
Study: 19447387
Drug: Non-EPA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-EPA treatment
Study: 17431702
Drug: Albumin therapy
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin therapy (40 g or 80 g within 24 h from symptom onset)
Study: 9273030
Drug: Transconjunctival injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transconjunctival injection
Study: 9273030
Drug: Transcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous injection
Study: 3119785
Drug: 18 or
Normalized name: Panlor Reformulated Jan 2018 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 or 24 Gy of radiation therapy (RT) to craniospinal plus abdominal RT including the ovaries
Study: 3119785
Drug: 18 or
Normalized name: Panlor Reformulated Jan 2018 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 or 24 Gy of radiation therapy (RT) to craniospinal RT
Study: 3119785
Drug: 18 or
Normalized name: Panlor Reformulated Jan 2018 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 or 24 Gy of radiation therapy (RT) to cranial RT
Study: 28774856
Drug: Modafinil 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 3.2 mg/kg (in mice)
Study: 28774856
Drug: Modafinil 10
Normalized name: modafinil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 10 mg/kg (in mice)
Study: 28774856
Drug: Modafinil 32
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 32 mg/kg (in mice)
Study: 22189151
Drug: Polyalkylamide gel
Normalized name: polyacrylamide (10000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyalkylamide gel (PAIG) treatment
Study: 22189151
Drug: Delayed PAIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed PAIG injections (12 weeks later)
Study: 9758086
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS alone or in combination with HCTZ
Study: 3377211
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of fentanyl 10 micrograms/ml with bupivacaine 0.1%
Study: 3377211
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of morphine 0.1 mg/ml with bupivacaine 0.1%
Study: 29603591
Drug: Vorinostat 430
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 430 mg/m2/day (days 1-4; 8-11) in combination with isotretinoin 80 mg/m2/dose (days 1-14)
Study: 29603591
Drug: Vorinostat 430
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 430 mg/m2/day (days 1-4; 8-11)
Study: 26503614
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) for cows' milk allergy
Study: 25973439
Drug: apremilast 20
Normalized name: apremilast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apremilast 20 mg BID
Study: 25973439
Drug: apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apremilast 30 mg BID
Study: 20944074
Drug: EZG (RTG)
Normalized name: EZG
DrugBank: Ezogabine (DB04953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZG (RTG) 600 mg/d
Study: 20944074
Drug: EZG (RTG)
Normalized name: EZG
DrugBank: Ezogabine (DB04953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZG (RTG) 900 mg/d
Study: 12823389
Drug: Drotaverine hydrochloride
Normalized name: drotaverine hydrochloride
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotaverine hydrochloride (80 mg, intravenous, with possible repeat dose)
Study: 7851466
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tropisetron plus ketanserin
Study: 2647123
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg to 60 mg daily)
Study: 23351836
Drug: Internet-based aftercare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based aftercare with weekly writing tasks and therapeutic feedback, a patient forum, a self-test and relaxation exercises (n = 400)
Study: 21288539
Drug: C‐AT (computer-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐AT (computer-assisted treatment program, My Sentence Builder)